Details of the Drug Combinations

General Information of This Drug (ID: DMG0C81)

Drug Name

Deferoxamine DMG0C81

Synonyms

deferoxamine; Desferrioxamine B; DESFERRIOXAMINE; Deferoxamine B; Deferrioxamine B; 70-51-9; Deferrioxamine; Deferoxamin; Deferoxaminum; DFOM; Desferin; Desferral; Desferrin; Desferex; Desferan; N-Benzoylferrioxamine B; Desferal; DF B; DFOA; Deferoxamide B; Deferoxamina; NSC-527604; Ferrioxamine B, N-benzoyl-; Desferriferrioxamin B; UNII-J06Y7MXW4D; Deferoxamine [USAN:INN]; Deferoxaminum [INN-Latin]; Deferoxamina ; Deferoxamine

Indication

Disease Entry	ICD 11	Status	REF
Acute iron or aluminum toxicity	FB83.20	Approved	[1]
Subarachnoid hemorrhage	8B01	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 1/2	[3]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Deferasirox + Deferoxamine	DCQYS9G	Deferasirox	Sickle Cell Disease	[4]
Deferoxamine + Deferiprone	DC7PNEB	Deferiprone	Cardiovascular Diseases	[5]
Deferoxamine + Deferiprone	DCUXU5C	Deferiprone	Hemochromatosis	[6]
Deferoxamine + Hydroxyurea	DCKXEXF	Hydroxyurea	Iron Overload	[7]
------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 207384.
2	Deferoxamine FDA Label
3	ClinicalTrials.gov (NCT04333550) Application of Desferal to Treat COVID-19. U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT00110617) Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
5	ClinicalTrials.gov (NCT00115349) Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
6	ClinicalTrials.gov (NCT00349453) Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients
7	ClinicalTrials.gov (NCT04292314) Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia